LUPUS NEPHRITIS (LN)

This study tests a new treatment called YTS109 for people with severe autoimmune diseases like lupus and vasculitis that haven't gotten better with standard care. About 18 adults will get a single infusion of these specially designed immune cells. The main goal is to see if the t…

This early-stage study tests a new cell therapy called YTS109 in 18 adults with autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of these specially designed cells. The main goal is to chec…

This study tests whether newer biologic drugs (belimumab or telitacicept) can control active lupus kidney disease better than the standard treatment. About 50 adults with biopsy-confirmed lupus nephritis will receive either a biologic plus steroids, standard therapy (mycophenolat…

This study tests a new drug (HLX79) combined with an existing antibody treatment (rituximab) in people with active kidney inflammation called glomerulonephritis. The goal is to see if the combination is safe and helps control the disease better than rituximab alone. About 24 adul…

This study tests a treatment called CART19 for teens and young adults (ages 12-29) with severe lupus that hasn't improved with standard care. CART19 uses a patient's own immune cells, modified to target and calm the overactive immune system causing lupus. The goal is to control t…

This study tests an experimental tablet called HSK39297 in people with lupus nephritis, a kidney complication of lupus. About 105 adults will receive either the drug or a placebo daily for several months. The main goal is to see if the drug reduces protein in the urine, a sign of…

This early-phase study tests whether a new drug, ONTO1, is safe and tolerable for people with lupus nephritis or systemic lupus erythematosus. About 61 participants will receive ONTO1 alongside standard lupus treatments like mycophenolate mofetil. The goal is to find the highest …

This early-stage study tests experimental bispecific antibody drugs in 90 adults with lupus nephritis that has not responded well to other treatments. The main goal is to see if the drugs are safe and tolerable over the long term. Researchers will also monitor side effects, drug …

This study tests a new treatment using a patient's own immune cells, called CAR T cells, to fight severe lupus that hasn't responded to other therapies. About 18 people aged 3 to 65 with lupus or lupus kidney disease will receive the cells and be monitored for safety and effectiv…

This early-stage study tests a new treatment called YTS109 for people with severe autoimmune diseases like lupus and scleroderma that have not responded to standard therapies. About 18 adults will receive a single infusion of these specially designed cells to see if it is safe an…

This early-stage study tests a new drug called HB2198 in about 30 adults with moderate-to-severe lupus, including kidney inflammation. The drug is designed to target and deplete certain immune cells (B cells) that drive the disease. The main goals are to check safety, find the ri…

This study is a fully online registry for adults and children with lupus. It aims to collect information about diagnosis, treatment, and quality of life through surveys every six months. No travel is required—everything is done from home. The goal is to better understand lupus an…